1[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235
2[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B
3[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924
4[4]De Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction.Observations from the TIMI 14 trial[J]. Circulation,2000, 101(3) :239 - 243
5[5]Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲa inhibition: the GUSTO V randomised trial[J]. Lancet, 2001, 357(9272) :1905 - 1914
6[6]Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) - 3 PLUS randomized trial in acute myocardial infarction [J ]. Circulation, 2003, 108(2): 135 - 142
7[7]Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial[J]. Circulation, 2002, 105(14): 1642 - 1649
8[8]Simoons M, Krzeminska - Pakula M, Alonso A, et al.Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study[J].Eur Heart J, 2002, 23 (16) :1282 - 1290
5Taylor DW, Barnett H J, Haynes RB, et al. Low-dose and highdose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial: ASA and Carotid Endarterectomy (ACE) Trial collaborators. Lancet, 1999,353 : 2179-2184.
6Gum PA,Kottke MK,Poggio ED,et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cadio, 2001,88 : 230-235.
7Mehta SR, Yusuf S, Peters R J, et al. For the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trim Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study. Lancet,2001,358: 527-533.
8Steinhubl SR,Berger PB,Mann III JT,et al. For the CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial ( CREDO ). JAMA, 2002,288: 2411-2420.
9Bhatt DL, Fox KA, Haeke W,et al. For the Clopidogrel for High Atherothrombotie Risk and Ischemie Stabilization, Management, and Avoidance (CHARISMA) Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med,2006,354: 1706-1717.
10Muller I, Besta F, Schulz C, et al. Prevalence of clop idogrel non- responders among patientswith stable angina pectofis scheduled for elective coronary stent placement. Thromb Haemost, 2003,89: 7832-7871.
